Early Data On Amgen’s AMG 133 Show Potential Durability, Dosing Advantage In Obesity

The drug is dosed once every four weeks – compared with Mounjaro and Wegovy’s weekly dosing – but the company also signaled it is considering extended dosing intervals.

Amgen announced data on AMG 133 in obesity • Source: Shutterstock

More from Clinical Trials

More from R&D